Paolo Tarantino: Honored to co-chair the New Drugs on the Horizon Session at the EORTC-NCI-AACR Triple Meeting
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared on LinkedIn:
“Such a honor to co-chair the New Drugs on the Horizon Session with Timothy Yap at the EORTC-NCI-AACR Triple Meeting.
Brings hope to see so much innovation in the oncology pipeline, with novel ADCs, IO and targeted drugs all promising to help us treat cancer better.
Soon.”
More posts featuring Paolo Tarantino on oncodaily.com
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023